Acorda Therapeutics Inc recorded an increase in cost of sales by 14.63 % year on year, relative to one quarter ago cost of sales fell by -33.77 % in Q1.
The company relies on third-party manufacturers for the production of commercial supplies of Ampyra and Inbrija. It depends on collaborators and distributors to commercialize Inbrija and Ampyra outside the United States. Following the termination of its collaboration agreement with Biogen, the company plans to establish additional collaborations and distribution arrangements to transition the commercialization of Fampyra. The company faces risks related to the complex and regulated manufacturing processes for pharmaceuticals, which may impact the commercial supply of Inbrija. Third-party payers may not provide reimbursement for Inbrija at acceptable rates or may impose restrictive prior authorization requirements that could limit or prevent prescriptions. The company faces competition from generic versions of Ampyra in the United States and a generic version of Fampyra in Germany. Biogen is identified as a supplier in company filings.
Acorda Therapeutics Inc's Comment on Supply Chain
The company relies on third-party manufacturers for the production of commercial supplies of Ampyra and Inbrija. It depends on collaborators and distributors to commercialize Inbrija and Ampyra outside the United States. Following the termination of its collaboration agreement with Biogen, the company plans to establish additional collaborations and distribution arrangements to transition the commercialization of Fampyra. The company faces risks related to the complex and regulated manufacturing processes for pharmaceuticals, which may impact the commercial supply of Inbrija. Third-party payers may not provide reimbursement for Inbrija at acceptable rates or may impose restrictive prior authorization requirements that could limit or prevent prescriptions. The company faces competition from generic versions of Ampyra in the United States and a generic version of Fampyra in Germany. Biogen is identified as a supplier in company filings.
Sources:
Acorda Therapeutics Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Acorda Therapeutics Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
